Literature DB >> 27687958

Treatment of diabetes: Crossing to the other side.

Nikitas P Skliros1, Charalambos Vlachopoulos2, Dimitrios Tousoulis1.   

Abstract

Type 2 diabetes mellitus affects nearly four hundred million people worldwide, and one of its major complications is cardiovascular disease. The evaluation of the effectiveness and safety of antidiabetic medication has been a challenging issue. Large clinical trials of new antidiabetic medications have used the non-inferiority approach to ensure primary safety of the drug before its incorporation into clinical practice. Currently, the trend is to prove superiority, that is, to prove that the new drug has additional beneficial effects to those of standard medications. In this review, we present the results of recent clinical trials on type 2 diabetes mellitus medications and outline what can be anticipated from ongoing clinical trials.
Copyright © 2016 Hellenic Cardiological Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antidiabetic drugs; Cardiovascular disease; Cardiovascular outcome trials; Cardiovascular safety; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2016        PMID: 27687958     DOI: 10.1016/j.hjc.2016.07.002

Source DB:  PubMed          Journal:  Hellenic J Cardiol        ISSN: 1109-9666


  2 in total

Review 1.  In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update.

Authors:  Lina T Al Kury; Aya Abdoh; Kamel Ikbariah; Bassem Sadek; Mohamed Mahgoub
Journal:  Molecules       Date:  2021-12-29       Impact factor: 4.411

2.  Hematopoietically expressed homeobox gene is associated with type 2 diabetes in KK Cg-Ay/J mice and a Taiwanese Han Chinese population.

Authors:  Chi-Cheng Lu; Yng-Tay Chen; Shih-Yin Chen; Yuan-Man Hsu; Chyi-Chyang Lin; Je-Wei Tsao; Yu-Ning Juan; Jai-Sing Yang; Fuu-Jen Tsai
Journal:  Exp Ther Med       Date:  2018-05-10       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.